Astria Therapeutics (NASDAQ:ATXS) Receives Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a research report released on Wednesday,Benzinga reports. Cantor Fitzgerald currently has a $47.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Astria Therapeutics’ FY2025 earnings at ($2.38) EPS. ATXS has been the topic of […]
Cantor Fitzgerald reiterated their overweight rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a research report released on Wednesday,Benzinga reports. Cantor Fitzgerald currently has a $47.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Astria Therapeutics’ FY2025 earnings at ($2.38) EPS. ATXS has been the topic of […]
